Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 169

1.

Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis.

Devos D, Cabantchik ZI, Moreau C, Danel V, Mahoney-Sanchez L, Bouchaoui H, Gouel F, Rolland AS, Duce JA, Devedjian JC; FAIRPARK-II and FAIRALS-II studygroups.

J Neural Transm (Vienna). 2020 Feb;127(2):189-203. doi: 10.1007/s00702-019-02138-1. Epub 2020 Jan 7. Review.

PMID:
31912279
2.

Iron as a therapeutic target for Parkinson's disease.

Moreau C, Duce JA, Rascol O, Devedjian JC, Berg D, Dexter D, Cabantchik ZI, Bush AI, Devos D; FAIRPARK-II study group.

Mov Disord. 2018 Apr;33(4):568-574. doi: 10.1002/mds.27275. Epub 2018 Jan 30. Review. No abstract available.

PMID:
29380903
3.

Could Conservative Iron Chelation Lead to Neuroprotection in Amyotrophic Lateral Sclerosis?

Moreau C, Danel V, Devedjian JC, Grolez G, Timmerman K, Laloux C, Petrault M, Gouel F, Jonneaux A, Dutheil M, Lachaud C, Lopes R, Kuchcinski G, Auger F, Kyheng M, Duhamel A, Pérez T, Pradat PF, Blasco H, Veyrat-Durebex C, Corcia P, Oeckl P, Otto M, Dupuis L, Garçon G, Defebvre L, Cabantchik ZI, Duce J, Bordet R, Devos D.

Antioxid Redox Signal. 2018 Sep 10;29(8):742-748. doi: 10.1089/ars.2017.7493. Epub 2018 Feb 8.

4.

In Search for Symbolic Qualities of Iron: The Metal of Life.

Cabantchik ZI.

Front Pharmacol. 2016 Aug 3;7:220. doi: 10.3389/fphar.2016.00220. eCollection 2016. No abstract available.

5.

GLP-1-RA Corrects Mitochondrial Labile Iron Accumulation and Improves β-Cell Function in Type 2 Wolfram Syndrome.

Danielpur L, Sohn YS, Karmi O, Fogel C, Zinger A, Abu-Libdeh A, Israeli T, Riahi Y, Pappo O, Birk R, Zangen DH, Mittler R, Cabantchik ZI, Cerasi E, Nechushtai R, Leibowitz G.

J Clin Endocrinol Metab. 2016 Oct;101(10):3592-3599. Epub 2016 Jul 26.

PMID:
27459537
6.

From one Nobel Prize (P. Ehrlich) to another (Tu Youyou): 100 years of chemotherapy of infectious diseases.

Cabantchik ZI, Drakesmith H.

Clin Microbiol Infect. 2016 Mar;22(3):213-4. doi: 10.1016/j.cmi.2015.11.011. Epub 2015 Dec 7. No abstract available.

7.

Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders.

de Swart L, Hendriks JC, van der Vorm LN, Cabantchik ZI, Evans PJ, Hod EA, Brittenham GM, Furman Y, Wojczyk B, Janssen MC, Porter JB, Mattijssen VE, Biemond BJ, MacKenzie MA, Origa R, Galanello R, Hider RC, Swinkels DW.

Haematologica. 2016 Jan;101(1):38-45. doi: 10.3324/haematol.2015.133983. Epub 2015 Sep 18.

8.

Iron and oxidative stress in cardiomyopathy in thalassemia.

Berdoukas V, Coates TD, Cabantchik ZI.

Free Radic Biol Med. 2015 Nov;88(Pt A):3-9. doi: 10.1016/j.freeradbiomed.2015.07.019. Epub 2015 Jul 26. Review.

PMID:
26216855
9.

The Labile Side of Iron Supplementation in CKD.

Slotki I, Cabantchik ZI.

J Am Soc Nephrol. 2015 Nov;26(11):2612-9. doi: 10.1681/ASN.2015010052. Epub 2015 May 21. Review.

10.

Iron overload and apoptosis of HL-1 cardiomyocytes: effects of calcium channel blockade.

Chen MP, Cabantchik ZI, Chan S, Chan GC, Cheung YF.

PLoS One. 2014 Nov 12;9(11):e112915. doi: 10.1371/journal.pone.0112915. eCollection 2014.

11.

Labile iron in cells and body fluids: physiology, pathology, and pharmacology.

Cabantchik ZI.

Front Pharmacol. 2014 Mar 13;5:45. doi: 10.3389/fphar.2014.00045. eCollection 2014. Review.

12.

A decisional algorithm to start iron chelation in patients with beta thalassemia.

Danjou F, Cabantchik ZI, Origa R, Moi P, Marcias M, Barella S, Defraia E, Dessì C, Foschini ML, Giagu N, Leoni GB, Morittu M, Galanello R.

Haematologica. 2014 Mar;99(3):e38-40. doi: 10.3324/haematol.2013.098202. No abstract available.

13.

Regional siderosis: a new challenge for iron chelation therapy.

Cabantchik ZI, Munnich A, Youdim MB, Devos D.

Front Pharmacol. 2013 Dec 31;4:167. doi: 10.3389/fphar.2013.00167. Review.

14.

Targeting chelatable iron as a therapeutic modality in Parkinson's disease.

Devos D, Moreau C, Devedjian JC, Kluza J, Petrault M, Laloux C, Jonneaux A, Ryckewaert G, Garçon G, Rouaix N, Duhamel A, Jissendi P, Dujardin K, Auger F, Ravasi L, Hopes L, Grolez G, Firdaus W, Sablonnière B, Strubi-Vuillaume I, Zahr N, Destée A, Corvol JC, Pöltl D, Leist M, Rose C, Defebvre L, Marchetti P, Cabantchik ZI, Bordet R.

Antioxid Redox Signal. 2014 Jul 10;21(2):195-210. doi: 10.1089/ars.2013.5593. Epub 2014 Feb 6.

15.

Nutrient-deprivation autophagy factor-1 (NAF-1): biochemical properties of a novel cellular target for anti-diabetic drugs.

Tamir S, Zuris JA, Agranat L, Lipper CH, Conlan AR, Michaeli D, Harir Y, Paddock ML, Mittler R, Cabantchik ZI, Jennings PA, Nechushtai R.

PLoS One. 2013 May 22;8(5):e61202. doi: 10.1371/journal.pone.0061202. Print 2013.

16.

Characterization of Arabidopsis NEET reveals an ancient role for NEET proteins in iron metabolism.

Nechushtai R, Conlan AR, Harir Y, Song L, Yogev O, Eisenberg-Domovich Y, Livnah O, Michaeli D, Rosen R, Ma V, Luo Y, Zuris JA, Paddock ML, Cabantchik ZI, Jennings PA, Mittler R.

Plant Cell. 2012 May;24(5):2139-54. doi: 10.1105/tpc.112.097634. Epub 2012 May 4.

17.

The role of endocytic pathways in cellular uptake of plasma non-transferrin iron.

Sohn YS, Ghoti H, Breuer W, Rachmilewitz E, Attar S, Weiss G, Cabantchik ZI.

Haematologica. 2012 May;97(5):670-8. doi: 10.3324/haematol.2011.054858. Epub 2011 Dec 16.

18.

Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients.

Breuer W, Ghoti H, Shattat A, Goldfarb A, Koren A, Levin C, Rachmilewitz E, Cabantchik ZI.

Am J Hematol. 2012 Jan;87(1):55-61. doi: 10.1002/ajh.22203. Epub 2011 Nov 28.

19.

On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure.

Pennell DJ, Carpenter JP, Roughton M, Cabantchik Z.

J Cardiovasc Magn Reson. 2011 Sep 12;13:45. doi: 10.1186/1532-429X-13-45.

20.

Facile transfer of [2Fe-2S] clusters from the diabetes drug target mitoNEET to an apo-acceptor protein.

Zuris JA, Harir Y, Conlan AR, Shvartsman M, Michaeli D, Tamir S, Paddock ML, Onuchic JN, Mittler R, Cabantchik ZI, Jennings PA, Nechushtai R.

Proc Natl Acad Sci U S A. 2011 Aug 9;108(32):13047-52. doi: 10.1073/pnas.1109986108. Epub 2011 Jul 25.

21.

Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal.

Sohn YS, Mitterstiller AM, Breuer W, Weiss G, Cabantchik ZI.

Br J Pharmacol. 2011 Sep;164(2b):406-18. doi: 10.1111/j.1476-5381.2010.01120.x.

22.

Prospective assessment of effects on iron-overload parameters of deferasirox therapy in patients with myelodysplastic syndromes.

Greenberg PL, Koller CA, Cabantchik ZI, Warsi G, Glynos T, Paley C, Schiffer C.

Leuk Res. 2010 Dec;34(12):1560-5. doi: 10.1016/j.leukres.2010.06.013. Epub 2010 Jul 8.

PMID:
20615548
23.

Transferrin-iron routing to the cytosol and mitochondria as studied by live and real-time fluorescence.

Shvartsman M, Fibach E, Cabantchik ZI.

Biochem J. 2010 Jul 1;429(1):185-93. doi: 10.1042/BJ20100213.

PMID:
20408812
24.

Iron redistribution as a therapeutic strategy for treating diseases of localized iron accumulation.

Kakhlon O, Breuer W, Munnich A, Cabantchik ZI.

Can J Physiol Pharmacol. 2010 Mar;88(3):187-96. doi: 10.1139/Y09-128. Review.

PMID:
20393584
25.

Transferrin therapy ameliorates disease in beta-thalassemic mice.

Li H, Rybicki AC, Suzuka SM, von Bonsdorff L, Breuer W, Hall CB, Cabantchik ZI, Bouhassira EE, Fabry ME, Ginzburg YZ.

Nat Med. 2010 Feb;16(2):177-82. doi: 10.1038/nm.2073. Epub 2010 Jan 24.

PMID:
20098432
26.

Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients.

Zanninelli G, Breuer W, Cabantchik ZI.

Br J Haematol. 2009 Dec;147(5):744-51. doi: 10.1111/j.1365-2141.2009.07907.x. Epub 2009 Sep 18.

PMID:
19764989
27.

Exogenous iron increases hemoglobin in beta-thalassemic mice.

Ginzburg YZ, Rybicki AC, Suzuka SM, Hall CB, Breuer W, Cabantchik ZI, Bouhassira EE, Fabry ME, Nagel RL.

Exp Hematol. 2009 Feb;37(2):172-83. doi: 10.1016/j.exphem.2008.10.004. Epub 2008 Dec 6.

PMID:
19059700
28.

Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation.

Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, Munnich A, Cabantchik ZI.

Blood. 2008 Dec 15;112(13):5219-27. doi: 10.1182/blood-2008-06-161919. Epub 2008 Sep 16.

PMID:
18796625
29.

Redistribution of accumulated cell iron: a modality of chelation with therapeutic implications.

Sohn YS, Breuer W, Munnich A, Cabantchik ZI.

Blood. 2008 Feb 1;111(3):1690-9. Epub 2007 Nov 1.

PMID:
17975016
30.

Non-transferrin-bound iron reaches mitochondria by a chelator-inaccessible mechanism: biological and clinical implications.

Shvartsman M, Kikkeri R, Shanzer A, Cabantchik ZI.

Am J Physiol Cell Physiol. 2007 Oct;293(4):C1383-94. Epub 2007 Aug 1.

31.

Intracellular labile iron.

Breuer W, Shvartsman M, Cabantchik ZI.

Int J Biochem Cell Biol. 2008;40(3):350-4. Epub 2007 Mar 19. Review.

PMID:
17451993
32.

Selective iron chelation in Friedreich ataxia: biologic and clinical implications.

Boddaert N, Le Quan Sang KH, Rötig A, Leroy-Willig A, Gallet S, Brunelle F, Sidi D, Thalabard JC, Munnich A, Cabantchik ZI.

Blood. 2007 Jul 1;110(1):401-8. Epub 2007 Mar 22.

PMID:
17379741
33.

Ineffective erythropoiesis in beta-thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin.

Gardenghi S, Marongiu MF, Ramos P, Guy E, Breda L, Chadburn A, Liu Y, Amariglio N, Rechavi G, Rachmilewitz EA, Breuer W, Cabantchik ZI, Wrighting DM, Andrews NC, de Sousa M, Giardina PJ, Grady RW, Rivella S.

Blood. 2007 Jun 1;109(11):5027-35. Epub 2007 Feb 13.

34.

Downregulation of hepcidin and haemojuvelin expression in the hepatocyte cell-line HepG2 induced by thalassaemic sera.

Weizer-Stern O, Adamsky K, Amariglio N, Levin C, Koren A, Breuer W, Rachmilewitz E, Breda L, Rivella S, Cabantchik ZI, Rechavi G.

Br J Haematol. 2006 Oct;135(1):129-38. Epub 2006 Aug 25.

PMID:
16939499
35.

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences.

Glickstein H, El RB, Link G, Breuer W, Konijn AM, Hershko C, Nick H, Cabantchik ZI.

Blood. 2006 Nov 1;108(9):3195-203. Epub 2006 Jul 11.

PMID:
16835377
36.

Characterization of mitochondrial iron uptake in HepG2 cells.

Mazariegos DI, Cabantchik ZI, Cassels BK, Núñez MT.

Biol Res. 2006;39(1):199-201.

37.

Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women.

van der A DL, Marx JJ, Grobbee DE, Kamphuis MH, Georgiou NA, van Kats-Renaud JH, Breuer W, Cabantchik ZI, Roest M, Voorbij HA, van der Schouw YT.

Circulation. 2006 Apr 25;113(16):1942-9. Epub 2006 Apr 17. Erratum in: Circulation. 2006 May 30;113(21):e784.

PMID:
16618820
38.

Objectives and mechanism of iron chelation therapy.

Hershko C, Link G, Konijn AM, Cabantchik ZI.

Ann N Y Acad Sci. 2005;1054:124-35. Review.

PMID:
16339658
39.

Role of iron in inducing oxidative stress in thalassemia: Can it be prevented by inhibition of absorption and by antioxidants?

Rachmilewitz EA, Weizer-Stern O, Adamsky K, Amariglio N, Rechavi G, Breda L, Rivella S, Cabantchik ZI.

Ann N Y Acad Sci. 2005;1054:118-23. Review.

PMID:
16339657
40.

Intracellular labile iron pools as direct targets of iron chelators: a fluorescence study of chelator action in living cells.

Glickstein H, El RB, Shvartsman M, Cabantchik ZI.

Blood. 2005 Nov 1;106(9):3242-50. Epub 2005 Jul 14.

PMID:
16020512
41.

Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform.

Jacobs EM, Hendriks JC, van Tits BL, Evans PJ, Breuer W, Liu DY, Jansen EH, Jauhiainen K, Sturm B, Porter JB, Scheiber-Mojdehkar B, von Bonsdorff L, Cabantchik ZI, Hider RC, Swinkels DW.

Anal Biochem. 2005 Jun 15;341(2):241-50.

PMID:
15907869
42.

LPI-labile plasma iron in iron overload.

Cabantchik ZI, Breuer W, Zanninelli G, Cianciulli P.

Best Pract Res Clin Haematol. 2005 Jun;18(2):277-87. Review.

PMID:
15737890
43.

Iron chelation therapy.

Hershko CM, Link GM, Konijn AM, Cabantchik ZI.

Curr Hematol Rep. 2005 Mar;4(2):110-6.

PMID:
15720959
44.

Redox active plasma iron in C282Y/C282Y hemochromatosis.

Le Lan C, Loréal O, Cohen T, Ropert M, Glickstein H, Lainé F, Pouchard M, Deugnier Y, Le Treut A, Breuer W, Cabantchik ZI, Brissot P.

Blood. 2005 Jun 1;105(11):4527-31. Epub 2005 Jan 25.

PMID:
15671444
45.

Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer's, Parkinson's, and other neurodegenerative diseases.

Zheng H, Weiner LM, Bar-Am O, Epsztejn S, Cabantchik ZI, Warshawsky A, Youdim MB, Fridkin M.

Bioorg Med Chem. 2005 Feb 1;13(3):773-83.

PMID:
15653345
46.

Serum chelatable redox-active iron is an independent predictor of mortality after myocardial infarction in individuals with diabetes.

Sulieman M, Asleh R, Cabantchik ZI, Breuer W, Aronson D, Suleiman A, Miller-Lotan R, Hammerman H, Levy AP.

Diabetes Care. 2004 Nov;27(11):2730-2. No abstract available.

PMID:
15505013
47.

Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator.

Pootrakul P, Breuer W, Sametband M, Sirankapracha P, Hershko C, Cabantchik ZI.

Blood. 2004 Sep 1;104(5):1504-10. Epub 2004 May 20.

PMID:
15155464
48.

Labile plasma iron in iron overload: redox activity and susceptibility to chelation.

Esposito BP, Breuer W, Sirankapracha P, Pootrakul P, Hershko C, Cabantchik ZI.

Blood. 2003 Oct 1;102(7):2670-7. Epub 2003 Jun 12.

PMID:
12805056
49.

Intracellular and extracellular labile iron pools.

Cabantchik ZI, Kakhlon O, Epsztejn S, Zanninelli G, Breuer W.

Adv Exp Med Biol. 2002;509:55-75. Review. No abstract available.

PMID:
12572989
50.

Effects of combined chelation treatment with pyridoxal isonicotinoyl hydrazone analogs and deferoxamine in hypertransfused rats and in iron-loaded rat heart cells.

Link G, Ponka P, Konijn AM, Breuer W, Cabantchik ZI, Hershko C.

Blood. 2003 May 15;101(10):4172-9. Epub 2003 Jan 2.

PMID:
12511418

Supplemental Content

Loading ...
Support Center